EWTX EDGEWISE THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, EDGEWISE THERAPEUTICS INC reported revenue of n/a, net income of −$57.3M and diluted EPS of −$0.53; for the fiscal year ended December 2025 revenue was n/a.
EWTX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$191M, net income −$168K (margin n/a), EPS −$1.63
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$159M, net income −$134K (margin n/a), EPS −$1.45
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$114M, net income −$100K (margin n/a), EPS −$1.57
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$71.7M, net income −$67.6M (margin n/a), EPS −$1.26
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$43.2M, net income −$42.8M (margin n/a), EPS −$1.14
EWTX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$57.3M, EPS −$0.53
- Quarter ended Mar 31, 2026: revenue n/a, net income −$49.0M, EPS −$0.46
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income $117M, EPS −$0.47
- Quarter ended Sep 30, 2025: revenue n/a, net income −$40.7M, EPS −$0.39
- Quarter ended Jun 30, 2025: revenue n/a, net income −$36.1M, EPS −$0.34
- Quarter ended Mar 31, 2025: revenue n/a, net income −$40.8M, EPS −$0.43
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income $94.0M, EPS −$0.42
- Quarter ended Sep 30, 2024: revenue n/a, net income −$34.1M, EPS −$0.36
- Quarter ended Jun 30, 2024: revenue n/a, net income −$31.5M, EPS −$0.34
- Quarter ended Mar 31, 2024: revenue n/a, net income −$28.5M, EPS −$0.33
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income $69.9M, EPS −$0.46
- Quarter ended Sep 30, 2023: revenue n/a, net income −$25.7M, EPS −$0.41
- Quarter ended Jun 30, 2023: revenue n/a, net income −$21.5M, EPS −$0.34
- Quarter ended Mar 31, 2023: revenue n/a, net income −$22.8M, EPS −$0.36
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$19.4M, EPS −$0.30
- Quarter ended Sep 30, 2022: revenue n/a, net income −$17.5M, EPS −$0.34
- Quarter ended Jun 30, 2022: revenue n/a, net income −$16.1M, EPS −$0.32
- Quarter ended Mar 31, 2022: revenue n/a, net income −$14.7M, EPS −$0.30
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$12.7M, EPS $3.70
- Quarter ended Sep 30, 2021: revenue n/a, net income −$12.9M, EPS −$0.26
EWTX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$144M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$109M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$91.9M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$52.6M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$33.5M, share buybacks n/a
EWTX balance sheet
- Jun 30, 2026: cash $72.3M, total assets $480M, total liabilities $31.6M, shareholders' equity $448M
- Mar 31, 2026: cash $33.2M, total assets $519M, total liabilities $25.3M, shareholders' equity $493M
- Dec 31, 2025: cash $61.1M, total assets $553M, total liabilities $30.3M, shareholders' equity $522M
- Sep 30, 2025: cash $46.0M, total assets $583M, total liabilities $24.8M, shareholders' equity $559M
- Jun 30, 2025: cash $43.4M, total assets $613M, total liabilities $24.3M, shareholders' equity $589M
- Mar 31, 2025: cash $49.9M, total assets $454M, total liabilities $24.7M, shareholders' equity $430M
- Dec 31, 2024: cash $41.7M, total assets $487M, total liabilities $27.6M, shareholders' equity $459M
- Sep 30, 2024: cash $44.8M, total assets $511M, total liabilities $22.4M, shareholders' equity $489M
Is EWTX profitable?
No. EDGEWISE THERAPEUTICS INC lost $29.6M over the last four quarters.
What is EWTX's EPS?
Diluted earnings per share over the last four quarters were −$1.85; −$0.53 in the latest quarter.